Apyx Medical assumed with a Buy at Lake Street

Lake Street analyst Frank Takkinen assumed coverage of Apyx Medical with a Buy rating and $5 price target. The recent selloff driven by the Q3 shortfall and guide down is "overdone," argues Takkinen, who expects the company "will act swiftly to shore up the balance sheet" and thinks it is likely Renuvion is cleared for use in conjunction with liposuction in Q2 of 2023, assuming the company does not have to conduct a clinical trial.